Uniunea Europeană - română - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - virusul gripei de suprafață (hemaglutinină și neuraminidază) de tulpina a / vietnam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccinuri - imunizarea activă împotriva subtipului h5n1 al virusului gripal a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Uniunea Europeană - română - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - pui - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Uniunea Europeană - română - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccinuri - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Uniunea Europeană - română - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccinuri - active immunisation against h5 subtype of influenza a virus.

Uniunea Europeană - română - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porci - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Uniunea Europeană - română - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - imunologii pentru aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Uniunea Europeană - română - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - imunologii pentru aves - pui - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).

Uniunea Europeană - română - EMA (European Medicines Agency)

resilience biomanufacturing ireland limited - (virion întreg, inactivat) care conține antigenul: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccinuri - profilaxia gripei într-o situație pandemică declarată oficial. vaccinul antigripal pandemic trebuie utilizat în conformitate cu orientările oficiale.

Uniunea Europeană - română - EMA (European Medicines Agency)

intervet international b.v. - celule asociate viu recombinant turcia herpesvirus (tulpina hvp360), exprimarea proteinei de fuziune a nd virus și vp2 proteine de ibd virus - aviare, virusul herpes (marek boala lui) + virusul bursitei infecțioase aviare (boala de gumboro) + virusul bolii de newcastle/paramixovirus - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.

Uniunea Europeană - română - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - vaccinuri pentru gripă - profilaxia gripei cauzate de virusul a (h1n1v) 2009. focetria ar trebui să fie utilizate în conformitate cu recomandările oficiale.